TAR-200 monotherapy shows greater than 80 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer
GlobeNewswire
New data from Phase 2b SunRISe-1 study show rapid achievement of complete response (CR) with 98 percent achieving a CR within 12..